Literature DB >> 7075921

Effect of a long-term acarbose therapy on the metabolic control of sulphonylurea-treated diabetic patients.

G Sachse, H Laube, E Mäser, K Federlin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7075921     DOI: 10.1007/bf00283759

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  5 in total

1.  Effect of the alpha-glucosidase-inhibitor BAY-g-5421 on blood glucose control of sulphonylurea-treated diabetics and insulin-treated diabetics.

Authors:  G Sachse; B Willms
Journal:  Diabetologia       Date:  1979-11       Impact factor: 10.122

2.  Alpha-glucoside hydrolase inhibition in diabetes.

Authors:  H Vierhapper; A Bratusch-Marrain; W Waldhäusl
Journal:  Lancet       Date:  1978 Dec 23-30       Impact factor: 79.321

3.  [Effect of glucosidase inhibitor, Bay g 5421 (acarbose), on the blood glucose in obese diabetic patients ty pe 2 (NIDDM) (author's transl)].

Authors:  H Laube; M Fouladfar; R Aubell; H Schmitz
Journal:  Arzneimittelforschung       Date:  1980

4.  Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidehydrolase inhibitor.

Authors:  R J Walton; I T Sherif; G A Noy; K G Alberti
Journal:  Br Med J       Date:  1979-01-27

5.  Long-term treatment of sulphonylurea-treated diabetics with the alpha-glucosidase inhibitor Bay g 5421 (acarbose)

Authors:  H Vierhapper; P Bratusch-Marrain; W Waldhäusl
Journal:  Diabetologia       Date:  1981-05       Impact factor: 10.122

  5 in total
  2 in total

1.  Acute and short term effects of intestinal alpha-glucosidase inhibition on gut hormone responses in man.

Authors:  L O Uttenthal; O O Ukponmwan; M Ghiglione; S R Bloom
Journal:  Dig Dis Sci       Date:  1987-02       Impact factor: 3.199

2.  Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin dependent diabetes.

Authors:  D R Buchanan; A Collier; E Rodrigues; A M Millar; R S Gray; B F Clarke
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.